MX375484B - Derivados de azabencimidazol como inhibidores de pi3k beta - Google Patents

Derivados de azabencimidazol como inhibidores de pi3k beta

Info

Publication number
MX375484B
MX375484B MX2018015709A MX2018015709A MX375484B MX 375484 B MX375484 B MX 375484B MX 2018015709 A MX2018015709 A MX 2018015709A MX 2018015709 A MX2018015709 A MX 2018015709A MX 375484 B MX375484 B MX 375484B
Authority
MX
Mexico
Prior art keywords
beta inhibitors
pi3k beta
azabenzimidazole derivatives
compounds
azabenzimidazole
Prior art date
Application number
MX2018015709A
Other languages
English (en)
Spanish (es)
Other versions
MX2018015709A (es
Inventor
Christophe Gabriel Marcel Demestre
Christophe Meyer
Didier Jean- Claude BERTHELOT
Elisabeth Thérèse Jeanne Pasquier
Guillaume Jean Maurice Mercey
Isabelle Noëlle Constance Pilatte
Laurence Anne Mevellec
Lieven Meerpoel
Olivier Alexis Georges Querolle
Patrick René Angibaud
Sophie Coupa
Virginie Sophie Poncelet
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2018015709A publication Critical patent/MX2018015709A/es
Publication of MX375484B publication Critical patent/MX375484B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2018015709A 2016-06-16 2017-06-15 Derivados de azabencimidazol como inhibidores de pi3k beta MX375484B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16174712 2016-06-16
PCT/EP2017/064672 WO2017216293A1 (en) 2016-06-16 2017-06-15 Azabenzimidazole derivatives as pi3k beta inhibitors

Publications (2)

Publication Number Publication Date
MX2018015709A MX2018015709A (es) 2019-03-21
MX375484B true MX375484B (es) 2025-03-06

Family

ID=56132833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015709A MX375484B (es) 2016-06-16 2017-06-15 Derivados de azabencimidazol como inhibidores de pi3k beta

Country Status (13)

Country Link
US (1) US20190263804A1 (enExample)
EP (1) EP3472147B1 (enExample)
JP (1) JP7158286B2 (enExample)
KR (1) KR102472198B1 (enExample)
CN (1) CN109311843B (enExample)
AU (1) AU2017286380B2 (enExample)
BR (1) BR112018076169A2 (enExample)
CA (1) CA3025746A1 (enExample)
EA (1) EA037871B1 (enExample)
ES (1) ES2818620T3 (enExample)
IL (1) IL263653A (enExample)
MX (1) MX375484B (enExample)
WO (1) WO2017216293A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3904350B1 (en) 2018-04-12 2023-08-23 Bayer Aktiengesellschaft N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
UA127065C2 (uk) 2018-04-25 2023-03-29 Баєр Акціенгезельшафт Нові гетероарил-триазольні та гетероарил-тетразольні сполуки як пестициди
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
MX2022000954A (es) 2019-07-23 2022-02-14 Bayer Ag Novedosos compuestos de heteroaril-triazol como plaguicidas.
CN110551101B (zh) * 2019-08-28 2020-11-24 沈阳药科大学 1、6-二取代-苯并五元杂环类衍生物及其用途
TW202128664A (zh) 2019-10-09 2021-08-01 德商拜耳廠股份有限公司 作為除害劑之新穎雜芳基三唑化合物
EP4097102A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
US20230140430A1 (en) 2020-01-27 2023-05-04 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP2023512230A (ja) 2020-01-27 2023-03-24 ブリストル-マイヤーズ スクイブ カンパニー トール様受容体7(TLR7)アゴニストとしてのC3置換1H-ピラゾロ[4,3-d]ピリミジン化合物
KR20220132602A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
US12485123B2 (en) 2020-01-27 2025-12-02 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists
KR20220132592A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
CN115210235A (zh) 2020-01-27 2022-10-18 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
KR20220132601A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
CN115151548A (zh) 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
MX2024010099A (es) * 2022-02-18 2024-08-28 Xizang Haisco Pharmaceutical Co Ltd Derivado de pirazolopiridina y aplicacion del mismo en medicina.
CN121001723A (zh) * 2023-04-27 2025-11-21 海思科医药集团股份有限公司 一种吡啶并吡唑衍生物的药物组合物及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177074A (en) * 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
JP2009528385A (ja) 2006-03-02 2009-08-06 スミスクライン・ビーチャム・コーポレイション Pi3キナーゼ阻害剤として用いるためのチアゾロン
EP2046333A4 (en) 2006-07-24 2010-09-15 Glaxosmithkline Llc THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
EP2173354A4 (en) 2007-08-09 2011-10-05 Glaxosmithkline Llc CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS
KR20160116045A (ko) * 2007-10-05 2016-10-06 베라스템, 인코포레이티드 피리미딘 치환된 퓨린 유도체
KR101653842B1 (ko) 2008-01-04 2016-09-02 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
CA2775942A1 (en) 2009-09-29 2011-04-07 Xcovery Holding Company Llc Pi3k (delta) selective inhibitors
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
PT2624696T (pt) 2010-10-06 2017-03-21 Glaxosmithkline Llc Derivados de benzimidazole como inibidores da cinase pi3
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
US9096605B2 (en) 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
US8906910B2 (en) 2011-12-20 2014-12-09 Glaxosmithkline Llc Imidazopyridine derivatives as PI3 kinase
US8778937B2 (en) 2011-12-20 2014-07-15 Glaxosmithkline Llc Benzimidazole boronic acid derivatives as PI3 kinase inhibitors

Also Published As

Publication number Publication date
JP2019518059A (ja) 2019-06-27
US20190263804A1 (en) 2019-08-29
ES2818620T3 (es) 2021-04-13
MX2018015709A (es) 2019-03-21
CA3025746A1 (en) 2017-12-21
EP3472147B1 (en) 2020-06-17
KR20190016976A (ko) 2019-02-19
BR112018076169A2 (pt) 2019-03-26
AU2017286380B2 (en) 2021-02-04
AU2017286380A1 (en) 2018-12-06
EA037871B1 (ru) 2021-05-28
EA201892734A1 (ru) 2019-05-31
CN109311843B (zh) 2021-10-08
EP3472147A1 (en) 2019-04-24
KR102472198B1 (ko) 2022-11-28
JP7158286B2 (ja) 2022-10-21
IL263653A (en) 2019-01-31
WO2017216293A1 (en) 2017-12-21
CN109311843A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
MX375484B (es) Derivados de azabencimidazol como inhibidores de pi3k beta
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2022005182A (es) Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.
MX2015017192A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
UY35237A (es) Composiciones que comprenden un compuesto de triazol
UY35238A (es) Composiciones que comprenden un compuesto de triazol
EA201692003A1 (ru) Макроциклические производные пиримидина
MX382601B (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
MX2020005944A (es) Analogos espirobiciclicos novedosos.
MX2015017512A (es) Compuestos 2,3-dihidrobenzofuran-5-ilicos como inhibidores de cinasas dyrk.
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
MX2016012668A (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1 ,4]diazepina como inhibidores de ros1.
MX382175B (es) Composiciones de profármaco de monometilfumarato
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX375485B (es) Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta
EA201992296A1 (ru) Производные хиноксалина и пиридопиразина в качестве ингибиторов pi3k-бета
PH12018501895A1 (en) Substituted nucleoside analogues for use as prmt5 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration